Arkolith/Insider Trading/BTAI/Form 4

Mehta Vimal

CEO and President, Director, 10% OwnerBioXcel Therapeutics, Inc. (BTAI) · full profile →Form 4 · filed Dec 17, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1K
Net Open-Market Flow
-$1K
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 16, 2024Sell(S)983$0.36$35461K
Dec 16, 2024Sell(S)2K$0.36$76860K
Dec 15, 2024Option exercise(M)4K——62K
Dec 14, 2024Option exercise(M)3K——58K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 15, 2024Option exercise(M)4K—$032K
Dec 14, 2024Option exercise(M)3K—$013K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-24-129462) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for BioXcel Therapeutics, Inc.

Build

Ask your agent about BTAI insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001104659-24-129462"
Ask your agent
Use Arkolith to summarize insider buying and selling at BioXcel Therapeutics, Inc.
over the last 90 days and cite the filings.